Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 14 12 2018
revised: 23 01 2019
accepted: 25 01 2019
pubmed: 4 2 2019
medline: 17 7 2019
entrez: 4 2 2019
Statut: ppublish

Résumé

The number of white matter lesions (WML) in brain MRI is the most established paraclinical tool to support the diagnosis of multiple sclerosis (MS) and to monitor its course. Diagnostic criteria have stipulated a minimum detectable diameter of 3 mm per WML, although this threshold is not evidence-based. We aimed to provide a rationale for a WML size threshold for three-dimensional MRI sequences at 3 T by comparing patients with relapsing-remitting MS (RRMS) to control subjects (CS). We analyzed MR images from two cohorts, obtained at scanners from two different vendors, each comprising patients with RRMS and CS. Both cohorts were examined with FLAIR and T1w sequences. In total, 232 patients with RRMS (Expanded Disability Status Scale: mean = 1.6 ± 1.2; age: mean = 36 ± 10) as well as 116 age- and sex-matched CS were studied. We calculated odds ratios across WML volumes. The WML size threshold, which discriminated best between patients and CS, was estimated with receiver operating characteristic curve analysis. In both cohorts, odds ratios increased continuously with increasing WML volumes, and discriminative power was highest at a WML size threshold corresponding to a diameter of about 3 mm. The stipulated WML size threshold of 3 mm in diameter for the diagnostic criteria of MS seems a reasonable choice for three-dimensional MRI sequences at 3 T.

Sections du résumé

BACKGROUND BACKGROUND
The number of white matter lesions (WML) in brain MRI is the most established paraclinical tool to support the diagnosis of multiple sclerosis (MS) and to monitor its course. Diagnostic criteria have stipulated a minimum detectable diameter of 3 mm per WML, although this threshold is not evidence-based. We aimed to provide a rationale for a WML size threshold for three-dimensional MRI sequences at 3 T by comparing patients with relapsing-remitting MS (RRMS) to control subjects (CS).
METHODS METHODS
We analyzed MR images from two cohorts, obtained at scanners from two different vendors, each comprising patients with RRMS and CS. Both cohorts were examined with FLAIR and T1w sequences. In total, 232 patients with RRMS (Expanded Disability Status Scale: mean = 1.6 ± 1.2; age: mean = 36 ± 10) as well as 116 age- and sex-matched CS were studied. We calculated odds ratios across WML volumes. The WML size threshold, which discriminated best between patients and CS, was estimated with receiver operating characteristic curve analysis.
RESULTS RESULTS
In both cohorts, odds ratios increased continuously with increasing WML volumes, and discriminative power was highest at a WML size threshold corresponding to a diameter of about 3 mm.
CONCLUSION CONCLUSIONS
The stipulated WML size threshold of 3 mm in diameter for the diagnostic criteria of MS seems a reasonable choice for three-dimensional MRI sequences at 3 T.

Identifiants

pubmed: 30711877
pii: S2211-0348(19)30043-4
doi: 10.1016/j.msard.2019.01.042
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-129

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

S Grahl (S)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; TUM Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

V Pongratz (V)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; TUM Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

P Schmidt (P)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; TUM Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

C Engl (C)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; TUM Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

M Bussas (M)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; TUM Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

A Radetz (A)

Neurology, University Medical Centre of the Johannes Gutenberg University Mainz and Neuroimaging Center of the Focus Program Translational Neuroscience (FTN-NIC), Langenbeckstr. 1, 55131, Mainz, Germany.

G Gonzalez-Escamilla (G)

Neurology, University Medical Centre of the Johannes Gutenberg University Mainz and Neuroimaging Center of the Focus Program Translational Neuroscience (FTN-NIC), Langenbeckstr. 1, 55131, Mainz, Germany.

S Groppa (S)

Neurology, University Medical Centre of the Johannes Gutenberg University Mainz and Neuroimaging Center of the Focus Program Translational Neuroscience (FTN-NIC), Langenbeckstr. 1, 55131, Mainz, Germany; German Competence Network Multiple Sclerosis (KKNMS).

F Zipp (F)

Neurology, University Medical Centre of the Johannes Gutenberg University Mainz and Neuroimaging Center of the Focus Program Translational Neuroscience (FTN-NIC), Langenbeckstr. 1, 55131, Mainz, Germany; German Competence Network Multiple Sclerosis (KKNMS).

C Lukas (C)

German Competence Network Multiple Sclerosis (KKNMS); Diagnostic and Interventional Radiology and Nuclear Medicine, St Josef Hospital, Ruhr, University Bochum, Gudrunstr. 56, 44791, Bochum, Germany.

J Kirschke (J)

Department of Neuroradiology, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

C Zimmer (C)

Department of Neuroradiology, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

M Hoshi (M)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

A Berthele (A)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany.

B Hemmer (B)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; German Competence Network Multiple Sclerosis (KKNMS); Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Str. 17, 81377, Munich, Germany.

M Mühlau (M)

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; TUM Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81541, Munich, Germany; German Competence Network Multiple Sclerosis (KKNMS). Electronic address: mark.muehlau@tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH